Cargando…
Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812207/ https://www.ncbi.nlm.nih.gov/pubmed/33490207 http://dx.doi.org/10.21037/atm-2020-130 |
| _version_ | 1783637619978010624 |
|---|---|
| author | Shing, Kit Kwok, Gerry Chiu, Joanne Cheung, Tan To Yau, Thomas |
| author_facet | Shing, Kit Kwok, Gerry Chiu, Joanne Cheung, Tan To Yau, Thomas |
| author_sort | Shing, Kit |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7812207 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78122072021-01-22 Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? Shing, Kit Kwok, Gerry Chiu, Joanne Cheung, Tan To Yau, Thomas Ann Transl Med Editorial Commentary AME Publishing Company 2020-12 /pmc/articles/PMC7812207/ /pubmed/33490207 http://dx.doi.org/10.21037/atm-2020-130 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Shing, Kit Kwok, Gerry Chiu, Joanne Cheung, Tan To Yau, Thomas Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title | Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title_full | Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title_fullStr | Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title_full_unstemmed | Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title_short | Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| title_sort | sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812207/ https://www.ncbi.nlm.nih.gov/pubmed/33490207 http://dx.doi.org/10.21037/atm-2020-130 |
| work_keys_str_mv | AT shingkit sorafenibplusdoxorubicininadvancedhepatocellularcarcinomapatientshopeorhype AT kwokgerry sorafenibplusdoxorubicininadvancedhepatocellularcarcinomapatientshopeorhype AT chiujoanne sorafenibplusdoxorubicininadvancedhepatocellularcarcinomapatientshopeorhype AT cheungtanto sorafenibplusdoxorubicininadvancedhepatocellularcarcinomapatientshopeorhype AT yauthomas sorafenibplusdoxorubicininadvancedhepatocellularcarcinomapatientshopeorhype |